Pricing Log in Create free account

Bicara Therapeutics Inc. (BCAX) vs Janux Therapeutics, Inc. (JANX)

Bicara Therapeutics Inc. and Janux Therapeutics, Inc. are both Biotechnology companies. Bicara Therapeutics Inc. is the larger, with a market value of $1.2B against $1.1B — 1.1× the size. Bicara Therapeutics Inc. has the higher net margin (0.00% vs −427.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Janux Therapeutics, Inc. leads on 6 and Bicara Therapeutics Inc. on 5.

Valuation

Metric BCAX JANX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 43.24 9.71
P/B 2.43 1.12 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 2.79 9.21
Earnings yield (18.47%) (9.95%) (33.15%)
Free cash flow yield (11.87%) (4.04%) (25.50%)

Profitability

Metric BCAX JANX Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (598.15%) 0.00%
Net margin 0.00% (427.47%) 0.00%
Free cash flow margin 0.00% (174.69%) 0.00%
Return on equity (41.01%) (10.70%) (56.36%)
Return on assets (38.38%) (10.06%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAX JANX Biotechnology median
Revenue growth (TTM) — 83.92% 6.02%
EPS growth (last fiscal year) 37.78% (42.97%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BCAX JANX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.59 16.35 4.72
Net debt to EBITDA 2.67 5.58 0.96

Dividend

Metric BCAX JANX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BCAX JANX Biotechnology median
Market cap 1.17b 1.06b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack